# DESCRIPTION

- introduce compounds as LOX and LOXL family members inhibitors

## BACKGROUND

- define LOX and its role in ECM
- describe LOX catalytic mechanism
- introduce LOX family members
- discuss LOX role in tissue remodelling
- discuss LOX role in primary cancer and metastasis
- describe LOX expression in various cancers
- discuss LOX association with metastasis and patient survival
- introduce LOXL2 and its role in cross-linking
- describe LOXL2 expression in various cancers
- discuss LOXL1 and its role in metastatic NSCLC
- describe LOXL3 and its role in EMT process
- introduce LOXL4 and its role in metastasis
- discuss LOX and LOXL implication in fibrotic diseases
- discuss LOX implication in cardiovascular disease
- discuss LOX association with Alzheimer's disease
- discuss LOXLs implication in pulmonary diseases
- discuss LOX inhibition in ocular conditions
- discuss LOX implication in inflammatory conditions
- discuss LOX implication in obesity and endometriosis

## BRIEF SUMMARY OF THE DISCLOSURE

- define compound of formula I
- specify ring A
- define R1
- specify o
- define RA1 and RA2
- define RA3 and RA4
- specify n
- define group
- specify Z
- define L1
- define R2
- define R3
- specify embodiments of R1
- specify embodiments of group
- specify embodiments of R3
- specify embodiments of ring A
- specify embodiments of compound of formula I
- define R1 options
- define R1 options
- define R1 options
- define R1 options
- define R1 options
- define R1 options
- define n options
- define R1 options
- define R1 options
- define R1 options
- define R1 options
- define R1 options
- define R1 options
- define RA1 options
- define RA1 options
- define RA1 options
- define R1 position
- define R1 substitution
- define RA1 and RA2 options
- define Z options
- define L1 options
- define compounds of formula (I)
- specify R1 in embodiments
- specify R1 in more embodiments
- specify R1 in even more embodiments
- specify R2 in embodiments
- specify RB1 and RB2 in embodiments
- specify RB1 and RB2 in more embodiments
- specify R2 in more embodiments
- specify R2 in even more embodiments
- specify R2 in additional embodiments
- specify R2 in further embodiments
- specify R2 in other embodiments
- specify R2 in more embodiments
- specify R2 in additional embodiments
- specify R2 in further embodiments
- specify R2 in other embodiments
- specify R2 in more embodiments
- specify R2 in additional embodiments
- specify R2 in further embodiments
- specify R2 in other embodiments
- define R2
- define R2 with heteroatoms
- define R2 with heteroaryl
- define R2 with unsubstituted heteroaryl
- define R2 with unsubstituted pyridyl
- define R2 with C1-6 alkyl and heterocyclyl
- define R2 with C1-6 alkyl and 6-membered heterocyclyl
- define R2 with ethyl and 6-membered heterocyclyl
- define R2 with ethyl and pyridyl
- define R2 with ethyl and imidazole
- define R2 with optionally substituted aryl
- define R2 with unsubstituted aryl
- define R2 with substituted aryl
- define R2 with phenyl
- define R2 with phenyl and ORA1
- define R2 with phenyl and OCH3
- define R2 with phenyl and halo
- define R2 with phenyl and F
- define R2 with thiomorpholinedioxide
- define compound of formula (I) with formula (XIIIa) or (XIIIb)
- define compound of formula (I) with formula (XIVa), (XIVb), (XIVc) or (XIVd)
- define R3 with homopiperazine ring
- define R3 as H
- define R3 with substituents
- define ring A with substituents
- define ring A with R1 and substituents
- define ring A with R1 and substituents
- define ring A with R1 and substituents
- define Z with substituents
- define Z with substituents and L1
- define Z with substituents and L1
- define compound of formula (I) with specific groups

## DETAILED DESCRIPTION

### Definitions

- define treating and treatment
- define therapeutically effective amount
- define halo and halogen
- define Cm-n
- define C1-6 alkyl
- define alkylene groups
- define C1-6 haloalkyl
- define C2-6 alkenyl
- define C2-6 alkynyl
- define C3-6 cycloalkyl
- define heterocyclyl, heterocyclic, and heterocycle
- describe monocyclic heterocyclic rings
- describe bicyclic heterocycles
- describe bridged ring systems
- describe spiro bi-cyclic ring systems
- define heterocyclyl-Cm-n alkyl
- define aromatic
- define aryl
- define heteroaryl
- describe monocyclic and bicyclic heteroaryl groups
- describe partially aromatic heteroaryl groups
- describe five-membered heteroaryl groups
- describe six-membered heteroaryl groups
- describe bicyclic heteroaryl groups with a six-membered ring fused to a five-membered ring
- describe bicyclic heteroaryl groups with two fused six-membered rings
- define heteroaryl-Cm-n alkyl-
- define optionally substituted
- describe optional substituents
- describe bond notation
- define ortho, meta, and para substitution
- define acyl group
- clarify meaning of "comprise" and "contain"
- clarify meaning of singular and plural
- describe applicability of features to other aspects
- describe combination of features and steps
- incorporate contents of concurrently filed papers
- describe molecular weight of compounds
- describe suitable features of compounds
- contemplate pharmaceutically acceptable salts
- list examples of acid addition salts
- list examples of base salts
- describe preparation of pharmaceutically acceptable salts
- describe methods for preparing salts
- describe degree of ionisation in salts
- define isomers, stereoisomers, diastereomers, and enantiomers
- describe chiral compounds and stereoisomers
- describe enantiomeric excess
- describe determination of stereochemistry
- describe isotopically-labelled compounds
- describe solvated and unsolvated forms
- describe polymorphism
- describe tautomeric forms
- describe in vivo effects of compounds
- describe metabolites
- incorporate contents of concurrently filed papers
- describe preparation of compounds
- describe isolation and purification of compounds
- describe crystalline and amorphous forms

### Pharmaceutical Compositions

- define pharmaceutical formulation
- reference conventional procedures
- list forms for administration
- describe composition preparation
- define effective amount for therapy
- specify dosage form amounts
- outline administration guidelines

### Therapeutic Uses and Applications

- provide compound for use as medicament
- provide compound for treatment of disease mediated by LOX
- provide use of compound in manufacture of medicament
- provide method of treating disease mediated by LOX
- clarify reference to treatment of disease mediated by LOX
- provide compound for use in treatment of certain diseases or conditions
- provide compound for selective inhibition of LOX
- provide compound for inhibition of two or more members of LOX family
- provide compound for treatment of proliferative disease
- discuss role of LOX in primary cancer and metastasis
- summarize evidence supporting role of LOX in primary tumour growth and metastasis
- discuss LOXL2 and its involvement in cross-linking of extracellular collagens and elastin
- summarize LOXL2 expression in various carcinomas
- discuss association of LOXL2 with poor prognosis and metastases
- discuss LOXL2 up-regulation and invasiveness of breast cancer cells
- discuss LOXL2 and LOXL4 in metastatic niche formation
- discuss LOXL2 expression in cholangiocarcinoma and HCC
- discuss regulation of LOXL2 transcription by HIF-1
- discuss LOXL2 and EMT
- discuss LOXL2 and Src/FAK pathway activation
- discuss LOXL2 as therapeutic target for treatment of primary and metastatic cancer
- discuss role of LOX in cancer metastasis
- summarize evidence supporting association of LOX with metastasis and poor survival
- discuss inhibition of LOX and its effect on metastasis
- discuss LOX regulation of invasion of cancer cells in vitro
- introduce LOX function
- LOX in tumour cell metastasis
- LOX in niche conditioning
- LOX in metastatic growth
- LOX in cancer cell survival
- LOX in phosphorylation of FAK
- LOX in collagen cross-linking
- LOX in cell proliferation and invasion
- LOX in host response to tumour surgery
- LOX inhibitor for cancer treatment
- LOX inhibitor for motility of tumour cells
- LOX inhibitor for dissemination and invasiveness
- LOX inhibitor for anti-invasive agent
- LOX inhibitor for prevention of cancer metastasis
- introduce LOX family and fibroblasts
- LOX family in extracellular matrix remodelling
- LOX family in desmoplasia
- LOX family in tumour ECM and stroma
- LOX family in tumour progression and metastasis
- LOX inhibitor for desmoplasia treatment
- LOX inhibitor for cancer treatment (various types)
- LOX inhibitor for myeloma and multiple myeloma
- LOX inhibitor for hematopoietic tumours
- LOX inhibitor for lymphomas
- LOX inhibitor for solid tumours of nervous system
- LOX inhibitor for melanoma and uveal melanoma
- LOX inhibitor for mixed types of cancer
- LOX inhibitor for benign proliferative disease
- LOX inhibitor for fibrotic diseases
- LOX in renal fibrosis
- LOX in lung fibrosis
- LOX in liver fibrosis
- LOX in fibrotic disorders (various types)
- LOX inhibitor for fibrotic disorders (various types)
- LOX in angiogenesis and vasculature permeability
- LOX in tumour angiogenesis
- LOX inhibitor for anti-angiogenic agent and vascular normalisation
- introduce therapeutic uses and applications
- describe treatment of ischemia and related diseases
- describe treatment of age-related macular degeneration
- describe treatment of inflammatory disorders
- describe treatment of acute inflammation
- describe treatment of chronic inflammatory disease
- describe treatment of rheumatoid arthritis and related diseases
- describe treatment of psoriasis and related diseases
- describe treatment of cardiovascular disease
- describe treatment of atherosclerosis
- describe treatment of myocardial fibrosis
- describe treatment of neurological conditions
- describe treatment of Alzheimer's disease
- describe treatment of nerve damage
- describe treatment of pulmonary diseases
- describe treatment of primary alveolar proteinosis
- describe treatment of bronchopulmonary dysplasia
- describe treatment of eye diseases
- describe treatment of glaucoma
- describe treatment of age-related macular degeneration
- describe treatment of other diseases
- describe treatment of obesity
- describe treatment of bacterial infections
- describe treatment of parasitic infections
- describe treatment of EGFR mediated conditions
- describe treatment of cancer
- describe treatment of viral infections
- describe treatment of Chlamydia infection
- describe treatment of genetic skin disorders
- relate LOX to EGFR
- describe use of LOX inhibitor in cancer treatment
- describe method of treating cancer with LOX inhibitor
- describe determining EGFR level in biological sample
- describe determining MATN2, pSMAD2, or HTRA1 level in biological sample
- describe method of increasing sensitivity rate of LOX inhibitor
- describe method of identifying subject with increased likelihood of responsiveness
- describe method of identifying subject with responsiveness
- describe method of determining treatment regimen
- describe LOX inhibitor downregulating MATN2 and/or activating SMAD2
- describe LOX inhibitor downregulating HTRA1
- describe LOX inhibitor inhibiting maturation of lysyl oxidase
- describe LOX inhibitor not inhibiting MAO-A and/or MAO-B

### Biomarkers

- introduce LOX inhibition therapy
- advantage of targeted therapy
- define LOX inhibitor
- source of lysyl oxidase
- assess enzymatic activity
- detect lysyl oxidase byproducts
- define inhibitor of lysyl oxidase
- quantify tumor inhibition
- assess lysyl oxidase expression
- use promoter analysis
- inhibit LOX by mRNA degradation
- use LOX inhibitor compounds
- predict response to LOX inhibition therapy
- define biomarker
- use biomarkers for diagnosis and prognosis
- define target molecule
- measure target molecule level
- define elevated level
- assess target molecule level
- use control samples
- define favourable response
- treat or prophylaxis
- relieve or attenuate disease
- define target molecule types
- use binding partners
- select specific binding partners
- use multiple target molecules
- use EGFR biomarker
- use MATN2 biomarker
- use HTRA1 biomarker
- use pSMAD2 biomarker
- identify expression signature
- increase sensitivity rate
- investigate target molecule level
- use immunological methods
- use labelled binding partners
- use nucleic acid binding partners
- use transcriptome analysis
- provide kits for biomarker methods
- define biomarkers
- specify elevated levels of biomarkers
- describe quantitative and qualitative outputs
- involve physiological measurements
- treat cancer with LOX inhibitor
- treat cancer with LOX inhibitor (alternative)
- treat cancer with LOX inhibitor (alternative)
- treat cancer with LOX inhibitor (alternative)
- describe LOX inhibitors' utility
- relate to lysyl oxidase inhibitor for cancer treatment
- relate to use of lysyl oxidase inhibitor for cancer treatment
- relate to method of treating or preventing cancer
- optionally determine EGFR level
- define EGFR overexpression
- describe EGFR overexpression measurement
- classify EGFR expression levels
- determine EGFR overexpression using IHC assay
- optionally determine MATN2 and pSMAD2 levels
- select cancer types
- inhibit maturation and catalytic activity of lysyl oxidase
- not inhibit MAO-A and/or MAO-B
- not inhibit DAO and/or hERG
- increase sensitivity rate of LOX inhibitor
- determine treatment regimen
- define MATN2
- describe MATN2's effect on EGFR
- downregulate MATN2 expression
- use MATN2 as biomarker
- identify subject with responsiveness to LOX inhibitor
- determine treatment regimen using MATN2
- describe SMAD2 and HTRA1

### In Vitro Methods

- describe in vitro methods for internalising EGFR or reducing EGFR expression

### Combination Therapies e.g. for the Treatment of Cancer

- motivate LOX inhibition for improving efficacy of other drugs
- describe LOX inhibition with siRNA
- describe LOX inhibition with chemotherapeutic drugs
- describe LOX inhibition with radiation
- describe LOX inhibition for reducing side effects
- describe LOX and LOXL2 inhibition for altering vascular permeability
- describe LOX inhibition for improving drug delivery
- describe LOX inhibition for reversing resistance to chemotherapeutics
- describe LOX inhibition for improving therapeutic response
- describe LOX inhibition for synergizing with gemcitabine
- describe LOX inhibition for improving outcome in surgically resectable disease
- describe compounds of the invention for use alone or in combination
- list categories of anti-cancer agents
- describe antiproliferative/antineoplastic drugs
- describe antimetabolites
- describe antibiotics
- describe antimitotic agents
- describe proteasome inhibitors
- describe interferon therapy
- describe topoisomerase inhibitors
- describe cytostatic agents
- describe anti-invasion agents
- describe inhibitors of growth factor function
- describe inhibitors of fibroblasts growth factor receptor family
- describe inhibitors of the hepatocyte growth factor family
- describe inhibitors of the insulin growth factor family
- describe modulators of protein regulators of cell apoptosis
- describe inhibitors of the platelet-derived growth factor family
- describe inhibitors of serine/threonine kinases
- describe combination treatment with radiotherapy

### Synthesis

- introduce synthetic methods
- discuss reaction conditions
- describe necessary starting materials
- discuss protecting groups
- provide examples of protecting groups
- describe deprotection conditions
- introduce general method for bridged piperidin-4-ones derivatives
- describe method A
- provide example of method A
- describe general methods for bridged homopiperazinone derivatives
- describe method B (Schmidt reaction)
- provide example of method B
- describe purification of resulting residue
- discuss regioisomers
- provide example of regioisomers
- conclude synthesis
- describe synthesis of compounds B1 and B1b
- provide NMR and HRMS data for compounds B1 and B1b
- describe synthesis of intermediate compound using method B
- provide NMR and HRMS data for intermediate compound
- describe method C (Beckmann reaction)
- describe synthesis of compounds using method C
- provide NMR data for compounds
- describe synthesis of intermediate compounds using method C
- describe method D (photochemical rearrangement of oxaziridines using continuous flow chemistry)
- describe synthesis of oxaziridine using method D
- describe photochemical rearrangement of oxaziridine using continuous flow chemistry
- describe synthesis of compound using method D
- provide NMR data for major isomer of oxaziridine
- provide HRMS data for major isomer of oxaziridine
- provide NMR data for minor isomer of oxaziridine
- provide HRMS data for minor isomer of oxaziridine
- conclude synthesis of compounds
- perform photochemical rearrangement
- describe resulting compounds
- outline general methods for reduction
- describe method E
- apply method E to specific compound
- describe resulting compound
- apply method E to another compound
- describe resulting compound
- outline alternative method for intermediate
- describe reduction of bridged homopiperazinone
- describe resulting compound
- describe debenzylation reaction
- describe resulting compound
- describe intermediate compound
- describe demethylation reaction
- describe resulting compound
- describe alkylation reaction
- describe synthesis
- provide NMR data
- describe synthesis of E11
- provide NMR data for E11
- describe synthesis of E12
- provide NMR data for E12
- describe method F
- describe synthesis of F1
- provide NMR data for F1
- describe synthesis of F2
- provide NMR data for F2
- describe method G
- describe synthesis of urea compound
- provide NMR data for urea compound
- describe synthesis of another urea compound
- provide NMR data for another urea compound
- synthesize compound
- synthesize intermediate
- synthesize intermediate
- synthesize target compound
- describe method H
- apply method H
- apply method H
- synthesize intermediate
- synthesize intermediate
- synthesize target compound
- describe method I
- apply method I
- synthesize intermediate
- synthesize target compound
- describe method E
- apply method E
- synthesize intermediate
- synthesize target compound
- describe method G
- apply method G
- synthesize intermediate F-6
- synthesize intermediate F-7
- describe method J for Boc deprotection and urea formation
- apply method J to form urea
- synthesize example 37
- form acetate
- oxidize to form aldehyde
- synthesize example 2
- form mesylate
- form oxazole
- describe general method K for N-alkyl linker synthesis
- apply method K to form nitrile
- form hydrochloric acid salt
- synthesize example 4
- form nitrile
- form hydrochloric acid salt
- synthesize example 5
- form nitrile
- form hydrochloric acid salt
- synthesize example 6
- form nitrile
- form hydrochloric acid salt
- synthesize example 7
- synthesize compound
- synthesize compound
- synthesize compound
- synthesize compound
- synthesize compound
- describe NMR data
- describe NMR data
- describe NMR data
- describe NMR data
- describe NMR data
- describe general method for synthesis
- describe method L
- synthesize compound using method L
- describe NMR data
- describe method M
- synthesize compound using method M
- describe NMR data
- describe synthesis of example compounds
- describe synthesis of example compounds
- describe synthesis of example compounds
- synthesize compound 411
- synthesize compound 620
- synthesize compound 320
- synthesize compound 95
- synthesize compound 62
- outline general method N
- synthesize compound with propylsulfonyl linker
- describe NMR and HRMS data
- introduce synthesis of compounds with N-aryl linker
- describe general method for synthesis
- outline synthesis of example compounds
- Synthesize compound 8721
- Synthesize intermediate compound
- Synthesize compound 8721 from intermediate
- Synthesize tert-butyl (1R,5S)-3-(1,1-dioxidothiomorpholine-4-carbonyl
- Describe method O
- Synthesize ((1S,5S)-6-(2,3-dihydrobenzo[b][1,4]dioxin-6
- Synthesize ((1S,5S)-6-(2,3-dihydrobenzo[b][1,4]dioxin-6
- Describe general methodology
- Synthesize (1,1-Dioxidothiomorpholino)((1S,5S)-6-(4-methoxycyclo
- Synthesize intermediate compound
- Synthesize (1,1-Dioxidothiomorpholino)((1S,5S)-6-(4-methoxycyclo
- Describe reaction conditions
- Describe workup and purification
- Provide NMR data
- Provide HRMS data
- Describe general applicability
- Provide additional examples

## Materials and Methods

### Cell Culture and Transfection

- describe cell culture conditions
- introduce transfection method
- detail cloning of LOX expression constructs

### Confocal Imaging and Imaging Analysis

- describe confocal imaging and analysis

### Animal Procedures

- outline animal procedures and regulations

### Oral Tolerability of LOX Inhibitors

- describe oral tolerability study

### In Vivo Tumour Models Studies

- introduce PDAC allografts
- describe SW620 xenografts
- detail MDA-MB-231 xenografts
- outline dosing and measurement procedures
- summarize tumour model studies

### LOX Inhibitor Treatment of a Transgenic Mouse Breast Cancer Model

- introduce MMTV-PyMT transgenic mouse model
- describe LOX inhibitor treatment
- detail tumour size measurement and calculation
- outline therapeutic efficacy assessment

